First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors

First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors. ClinicalTrials.gov record last updated 2026-05-12: active not recruiting. Enrollment is planned at 1123 participants. Primary completion is estimated at 2027-08-13. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: DB-1305/BNT325, Pembrolizumab, BNT327. Registered primary measures: Phase 1: Percentage of Participants with Dose-Limiting Toxicities (DLTs) as assessed by National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0.; Phase 1: Percentage of Participants with Treatment Emergent Adverse Events (TEAEs) as assessed by CTCAE v5.0.; Phase 1: Percentage of Participants with Serious Adverse Events (SAEs) as assessed by CTCAE v5.0..